Figure 2From: Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension Mean EQ-5D scores per patient at different times from the start of antihypertensive treatment. Not all patients completed all HRQoL instruments at each time point.Back to article page